Risk prediction models for incident primary cutaneous melanoma: A systematic review

JAMA Dermatology

Volumn 150, Issue 4, 2014, Pages 434-444

  Vuong, Kylie ^a   McGeechan, Kevin ^a   Armstrong, Bruce K ^a   Cust, Anne E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER INCIDENCE; CANCER RISK; CLINICAL PRACTICE; CUTANEOUS MELANOMA; EXTERNAL VALIDITY; HAIR COLOR; HUMAN; INTERNAL VALIDITY; LENTIGO; MEDICAL HISTORY; NEVUS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK PREDICTION MODEL; SENSITIVITY AND SPECIFICITY; SKIN EXAMINATION; SUNBURN; SYSTEMATIC REVIEW; VALIDATION PROCESS;

AREA UNDER CURVE; HUMANS; MELANOMA; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SKIN NEOPLASMS;

EID: 84898467204     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8890     Document Type: Review

References (49)

1. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril M-F, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst. 2004;96(10):785-795.
2. Cust AE, Jenkins MA, Goumas C, et al. Early-life sun exposure and risk of melanoma before age 40 years. Cancer Causes Control. 2011;22(6): 885-897.
3. Ahmed H, Naik G, Willoughby H, Edwards AG. Communicating risk. BMJ. 2012;344:e3996. doi:10.1136/bmj.e3996.
4. Whiteman DC, Green AC. A risk prediction tool for melanoma? Cancer Epidemiol Biomarkers Prev. 2005;14(4):761-763.
5. Vickers AJ. Prediction models in cancer care. CA Cancer J Clin. 2011;61(5):315-326.
6. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715-723.
7. Jackson A, Wilkinson C, Ranger M, Pill R, August P. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? a prospective study to validate a self administered risk score. BMJ. 1998;316(7124):34-39.
8. Quereux G, Nguyen JM, CaryM, Jumbou O, Lequeux Y, Dreno B. Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. Eur J Cancer Prev. 2012;21(6):588-595.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535.
10. Williams LH, Shors AR, BarlowWE, Solomon C, White E. Identifying persons at highest risk of melanoma using self-assessed risk factors. J Clin Exp Dermatol Res. 2011;2(6):129. doi:10.4172 /2155-9554.1000129.
11. Smith LA, QianM, Ng E, et al. Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
12. Stefanaki I, Panagiotou OA, Kodela E, et al. Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. PLoS One. 2013;8(2):e55712. doi:10.51371 /journal.pone.0055712.
13. Guther S, Ramrath K, Dyall-Smith D, Landthaler M, StolzW. Development of a targeted risk-group model for skin cancer screening based on more than 100, 000 total skin examinations. J Eur Acad Dermatol Venereol. 2012;26(1):86-94.
14. Mar V, Wolfe R, Kelly JW. Predicting melanoma risk for the Australian population. Australas J Dermatol. 2011;52(2):109-116.
15. Quereux G, Moyse D, Lequeux Y, et al. Development of an individual score for melanoma risk. Eur J Cancer Prev. 2011;20(3):217-224.
16. Fortes C, Mastroeni S, Bakos L, et al. Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev. 2010;19(5):393-400.
17. GoldbergMS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience: 2001-2005. J Am Acad Dermatol. 2007;57(1):60-66.
18. Fears TR, Guerry D IV, Pfeiffer RM, et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol. 2006;24(22):3590-3596.
19. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol. 2005;23(12):2669-2675.
20. Fargnoli MC, Piccolo D, Altobelli E, Formicone F, Chimenti S, Peris K. Constitutional and environmental risk factors for cutaneous melanoma in an Italian population: a case-control study. Melanoma Res. 2004;14(2):151-157.
21. Harbauer A, Binder M, Pehamberger H, Wolff K, Kittler H. Validity of an unsupervised self-administered questionnaire for self-assessment of melanoma risk. Melanoma Res. 2003;13(5):537-542.
22. Landi MT, Baccarelli A, Calista D, et al. Combined risk factors for melanoma in a Mediterranean population. Br J Cancer. 2001;85(9):1304-1310.
23. Barbini P, Cevenini G, Rubegni P, et al. Instrumental measurement of skin colour and skin type as risk factors for melanoma: a statistical classification procedure. Melanoma Res. 1998;8(5):439-447.
24. Marrett LD, KingWD, Walter SD, From L. Use of host factors to identify people at high risk for cutaneous malignant melanoma. CMAJ. 1992;147(4):445-453.
25. Garbe C, Buttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102(5):695-699.
26. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet. 1989;2(8661):487-490.
27. English DR, Armstrong BK. Identifying people at high risk of cutaneous malignant melanoma: results from a case-control study inWestern Australia. Br Med J (Clin Res Ed). 1988;296(6632): 1285-1288.
28. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
29. Steyerberg EW. Clinical Prediction Models. New York, NY: Springer; 2010.
30. Mallett S, Royston P, Waters R, Dutton S, Altman DG. Reporting performance of prognostic models in cancer: a review. BMC Med. 2010;8:21. doi:10.1186/1741-7015-8-21.
31. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604. doi:10.1136/bmj.b604.
32. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605. doi:10.1136/bmj.b605.
33. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reportingmethods in studies developing prognostic models in cancer: a review. BMC Med. 2010;8:20. doi:10.1186/1741-7015-8-20.
34. Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365-377.
35. Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2008;1(4):250-254.
36. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362(11):986-993.
37. Win AK, Macinnis RJ, Hopper JL, Jenkins MA. Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomarkers Prev. 2012;21(3):398-410.
38. DorvalM, Bouchard K, Chiquette J, et al. A focus group study on breast cancer risk presentation: one format does not fit all. Eur J Hum Genet. 2013;21(7):719-724.
39. Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953-2008are recent generations at higher or lower risk? Int J Cancer. 2013;132(2): 385-400.
40. Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58(5):687-700.
41. Vickers AJ, Elkin EB. Decision curve analysis: a novelmethod for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.
42. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ. 2009;338:b606. doi:10.1136/bmj.b606.
43. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144(3):201-209.
44. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. external validation, model updating, and impact assessment. Heart. 2012;98(9):691-698.
45. Geller AC, Zhang Z, Sober AJ, et al. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. J Am Acad Dermatol. 2003;48(1):34-41.
46. Stratigos AJ, Forsea AM, van der Leest RJ, et al. Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma: past, present and future. Br J Dermatol. 2012;167(suppl 2):99-104.
47. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150(3):194-198.
48. Losina E, Walensky RP, Geller A, et al. Visua reening for malignant anoma cost-effectiveness analysis. Arch Dermatol. 2007;143(1):21-28
49. Ferrini RL, Perlman M, Hill L. American College of Preventive Medicine policy statement: screening for skin cancer. Am J Prev Med. 1998;14(1):80-82.